Steven Erpelinck BSc. MBA
- AMS transporters
- PBPK modeling
We focus on nine societal areas.
TNO cooperates with companies, the public sector and other organisations, to apply our knowledge and expertise with and for others.
We develop knowledge not for its own sake, but for practical application.
TNO offers you the chance to do groundbreaking work and help customers and society with innovative, practical and smart solutions.
On our TNOTIME platform you can find blogs, interviews and background stories. Discover the field of TNO captured in photographs, animations, video and text. Share interesting articles and powerful infographics, or download whitepapers.
Microtracers can be used to increase the information density in your early clinical trials. The information on metabolites in First-In-Man studies will de-risk the clinical development trajectory because of the 100% certainty of not finding any human unique metabolites at a later stage. TNO is the only organization in Europe with a biomedical Accelerator Mass Spectrometer (AMS) that enables this research.
The focus and experience of TNO in the field of microtracer research extends to:
- Metabolite profiling and identification in First-In-Man studies
- Absolute bioavailability in early clinical development
- Early PK of biologicals (peptides, proteins, ADCs etc) and small molecules using microdosing
- Pediatric PK studies to optimize dosing strategies and increase recruitment rates dramatically
At the ASCPT, TNO will present its capabilities in the field of microtracer AMS studies showing that these studies will accelerate drug development. Advantages of our auto-combustion based AMS in comparison to the conventional graphitization based AMS will be demonstrated. In addition, we will show the strengths of using our simultaneous data acquisition using high resolution MS (for metabolite identification) and AMS (for metabolite quantification) approach.
We look forward to meeting you at our booth, number 40.